Shots:
- The NDA submission is based on two P-III studies (COUGH-1 & -2) involves assessing gefapixant (45/15mg, bid) vs PBO in 2,044 patients with RCC & UCC
- In both the studies, gefapixant resulted in the reduction of in 24hrs.-cough frequency @12 & 24wks respectively. Data were presented at ERS 2020
- Gefapixant is a selective P2X3 receptor antagonist for the potential treatment of refractory or unexplained chronic cough. The anticipated PDUFA date is Dec 21, 2021
Click here to read full press release/ article | Ref: Businesswire | Image: The Morning Call
The post Merck Reports the US FDA’s Acceptance of NDA for Review of Gefapixant to Treat Refractory or Unexplained Chronic Cough first appeared on PharmaShots.